Exane Derivatives’s Phathom Pharmaceuticals PHAT Stock Holding History

Exane Derivatives’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$94K	Buy	11,141 +5,267	+90%	+$54.2K	0.05%	269
2022 Q1	$79.9K	Buy	5,874 +816	+16%	+$13.2K	0.02%	498
2021 Q4	$99.5K	Hold	5,058	–	–	0.02%	442
2021 Q3	$162K	Buy	5,058 +2,221	+78%	+$73.8K	0.04%	440
2021 Q2	$96.6K	Buy	2,837 +871	+44%	+$31.2K	0.02%	539
2021 Q1	$73.8K	Sell	1,966 -661	-25%	-$27.7K	0.02%	468
2020 Q4	$87.3K	Hold	2,627	–	–	0.03%	411
2020 Q3	$96.3K	Sell	2,627 -150	-5%	-$5.2K	0.03%	302
2020 Q2	$91.4K	Sell	2,777 -325	-10%	-$12.5K	0.02%	307
2020 Q1	$80.1K	Buy	+3,102	New	+$104K	0.02%	307

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Exane Derivatives's PHAT Position: Q2 2022 in Review

Exane Derivatives increased its Phathom Pharmaceuticals (PHAT) stake by 90% in Q2 2022, buying an estimated $54.2K and bringing the position to 11,141 shares worth $94K. The position accounts for 0.05% of the portfolio, ranked #269.

Exane Derivatives first reported a position in PHAT in Q1 2020 and has held it in 10 quarters since. The position peaked at $162K in Q3 2021. 94 funds tracked by Wall St. Rank hold PHAT as of Q2 2022.

Exane Derivatives held 11,141 shares of Phathom Pharmaceuticals worth $94K as of Q2 2022.
Exane Derivatives bought 5,267 Phathom Pharmaceuticals shares in Q2 2022, an estimated $54.2K.
Phathom Pharmaceuticals made up 0.05% of Exane Derivatives's portfolio in Q2 2022, its #269 holding.
Exane Derivatives first reported a position in Phathom Pharmaceuticals in Q1 2020 and has held it in 10 quarters since.
Exane Derivatives's Phathom Pharmaceuticals position peaked at $162K in Q3 2021.
94 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.